Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL
Autoimmune CAR-T Could Sidestep Lymphodepletion
The allogeneic CAR-T developer announced a significant shift in its business strategy to develop its lead candidate in first-line consolidation of LBCL as the third-line disease setting becomes saturated.
